Trichostatin A decreases the levels of MeCP2 expression and phosphorylation and increases its chromatin binding...

Area of Science:

• Molecular biology
• Epigenetics
• Neuroscience

Background:

• MeCP2 protein is crucial for brain development and function, and its dysregulation is implicated in cancer and neurological disorders.
• Histone deacetylase (HDAC) inhibitors are used therapeutically, but their precise molecular mechanisms, especially concerning MeCP2 and histone acetylation, remain unclear.

Purpose of the Study:

• To investigate the effects of the HDAC inhibitor trichostatin A (TSA) on the MeCP2 protein.
• To elucidate the relationship between histone acetylation and MeCP2 function and regulation.

Main Methods:

• Cellular treatment with trichostatin A (TSA).
• Analysis of MeCP2 phosphorylation state and chromatin binding affinity.
• Assessment of MeCP2 protein levels and miR132 expression.

Main Results:

• TSA treatment reduced MeCP2 phosphorylation and increased its chromatin binding affinity.
• Despite chromatin reorganization, MeCP2 DNA binding dynamics were not significantly affected.
• HDAC inhibition led to decreased overall MeCP2 levels.
• miR132 expression increased upon TSA treatment and was identified as a factor in MeCP2 downregulation.

Conclusions:

• HDAC inhibition by TSA influences MeCP2 phosphorylation, chromatin binding, and overall levels.
• miR132 plays a role in the TSA-induced downregulation of MeCP2.
• These findings contribute to understanding the molecular mechanisms of HDAC inhibitors in diseases involving MeCP2.